Table 4.
Association between plasma biomarkers and ADM in participants after a 12-Month of lifestyle intervention.
| Low Adherence (n = 32) |
High Adherence (n = 35) |
|||
|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | p-Value | ||
| XOD | Crude OR | 1.00 (ref.) | 1.393 (0.640–3.032) | 0.404 |
| OR Adjusted 1 | 1.00 (ref.) | 1.438 (0.622–3.328) | 0.396 | |
| IL-1β | Crude OR | 1.00 (ref.) | 0.543 (0.263–1.119) | 0.098 |
| OR Adjusted 1 | 1.00 (ref.) | 0.679 (0.317–1.453) | 0.318 | |
| IL-1ra | Crude OR | 1.00 (ref.) | 0.474 (0.220–1.020) | 0.056 |
| OR Adjusted 1 | 1.00 (ref.) | 0.501 (0.227–1.107) | 0.087 | |
| IL-6 | Crude OR | 1.00 (ref.) | 0.907 (0.445–1.847) | 0.788 |
| OR Adjusted 1 | 1.00 (ref.) | 0.845 (0.404–1.769) | 0.655 | |
| TNFα | Crude OR | 1.00 (ref.) | 0.860 (0.415–1.780) | 0.683 |
| OR Adjusted 1 | 1.00 (ref.) | 0.983 (0.456–2.118) | 0.965 | |
| MCP-1 | Crude OR | 1.00 (ref.) | 0.782 (0.384–1.593) | 0.498 |
| OR Adjusted 1 | 1.00 (ref.) | 1.090 (0.498–2.386) | 0.830 | |
| MPO | Crude OR | 1.00 (ref.) | 0.611 (0.290–1.288) | 0.195 |
| OR Adjusted 1 | 1.00 (ref.) | 0.602 (0.278–1.301) | 0.197 | |
| RvD1 | Crude OR | 1.00 (ref.) | 1.371 (0.680–2.766) | 0.377 |
| OR Adjusted 1 | 1.00 (ref.) | 1.245 (0.597–2.597) | 0.559 | |
| CK-18 | Crude OR | 1.00 (ref.) | 0.326 (0.157–0.676) | 0.003 |
| OR Adjusted 1 | 1.00 (ref.) | 0.330 (0.152–0.714) | 0.005 | |
| Zonulin | Crude OR | 1.00 (ref.) | 1.432 (0.687–2.983) | 0.338 |
| OR Adjusted 1 | 1.00 (ref.) | 1.341 (0.629–2.858) | 0.447 | |
| EDA | Crude OR | 1.00 (ref.) | 0.206 (0.097–0.437) | <0.001 |
| OR Adjusted 1 | 1.00 (ref.) | 0.239 (0.111–0.517) | <0.001 | |
| Omentin | Crude OR | 1.00 (ref.) | 1.000 (0.486–2.059) | 1.000 |
| OR Adjusted 1 | 1.00 (ref.) | 1.014 (0.473–2.173) | 0.971 | |
| Chemerin | Crude OR | 1.00 (ref.) | 0.600 (0.293–1.227) | 0.162 |
| OR Adjusted 1 | 1.00 (ref.) | 0.597 (0.284–1.253) | 0.173 | |
| Leptin | Crude OR | 1.00 (ref.) | 1.062 (0.521–2.166) | 0.868 |
| OR Adjusted 1 | 1.00 (ref.) | 1.123 (0.537–2.350) | 0.759 | |
| Phenolic compounds | Crude OR | 1.00 (ref.) | 1.432 (0.687–2.983) | 0.338 |
| OR Adjusted 1 | 1.00 (ref.) | 1.595 (0.745–3.412) | 0.229 | |
| MDA | Crude OR | 1.00 (ref.) | 0.755 (0.351–1.622) | 0.471 |
| OR Adjusted 1 | 1.00 (ref.) | 0.751 (0.338–1.669) | 0.482 | |
| CAT | Crude OR | 1.00 (ref.) | 0.611 (0.290–1.288) | 0.195 |
| OR Adjusted 1 | 1.00 (ref.) | 0.629 (0.289–1.366) | 0.241 | |
| SOD | Crude OR | 1.00 (ref.) | 1.418 (0.672–2.992) | 0.359 |
| OR Adjusted 1 | 1.00 (ref.) | 1.552 (0.709–3.397) | 0.271 | |
| IFC | Crude OR | 1.00 (ref.) | 0.456 (0.229–0.910) | 0.026 |
| OR Adjusted 1 | 1.00 (ref.) | 0.516 (0.252–1.056) | 0.070 | |
| Endotoxin | Crude OR | 1.00 (ref.) | 0.818 (0.340–1.970) | 0.654 |
| OR Adjusted 1 | 1.00 (ref.) | 0.830 (0.344–2.005) | 0.679 |
Abbreviations: OR: odds ratio; OR adjusted 1: odds ratio after adjustments by intervention (diet and physical activity); ref.: reference; XOD: xanthine oxidase; IL-1β: interleukin-1β; IL-1ra: interleukin-1ra; IL-6: interleukin-6; TNFα: tumor necrosis factor α; MCP-1: monocyte chemoattractant protein 1; MPO: myeloperoxidase; RvD1: resolving D1; CK-18: cytokeratin-18; EDA: ectodysplasin-A.